You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Hypertension (high blood pressure)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:diseases:hypertension [01.04.2019] – [Notes and comments] sallieqhome:diseases:hypertension [01.04.2019] – [Notes and comments] sallieq
Line 169: Line 169:
 <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}})) <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}}))
  
-http://www.ncbi.nlm.nih.gov/pubmed/21061834+http://www.ncbi.nlm.nih.gov/pubmed/21061834 (USED on page --- //Sallie Q 01.04.2019// )
  
 CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels.
Line 182: Line 182:
  
 ~~~~ ~~~~
 +(part below ref. USED on page ---  --- //Sallie Q 01.04.2019// )
 Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}})) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}}))
  
Line 233: Line 233:
  
 PMID: PMID:
-21504378</blockquote> +21504378 (part  USED on page --- //Sallie Q 01.04.2019//</blockquote> 
home/diseases/hypertension.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.